PHILADELPHIA, PA — February 12, 2026 — Leads & Copy — Medicus Pharma Ltd. (NASDAQ:MDCX) CEO Dr. Raza Bokhari spoke with Matt Miller of Bloomberg World in a live interview on February 10, 2026, discussing the company’s strategy and the role of artificial intelligence in its drug development efforts.
Dr. Bokhari addressed the challenges facing biotech stocks and the company’s AI-driven approach. He highlighted Medicus Pharma’s leadership as both investors and operators, noting their commitment of nearly $14 million of personal capital at $4 per share to advance its pipeline. He expressed confidence that continued AI-enabled progress, regulatory optionality, and upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, should positively influence investor perception and unlock value, mirroring the positive trend observed in the first half of 2025 after an interim data analysis.
The interview also touched on the short-term volatility in biotech markets. Dr. Bokhari reiterated the company’s long-term belief in the potential of AI to transform therapy development.
Medicus Pharma is focused on accelerating the clinical development programs of novel therapeutics assets across multiple countries on three continents.
SkinJect Inc., a subsidiary of Medicus Pharma, is focused on commercializing a non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumor cells. A Phase 1 study (SKNJCT-001) in March 2021 demonstrated safety and tolerability, with six participants experiencing complete response. The company is currently conducting randomized, controlled, double-blind, multicenter clinical studies (SKNJCT-003) in the United States and Europe and (SKNJCT-004) in the United Arab Emirates.
In August 2025, Medicus Pharma entered a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. regarding a potential development or commercial arrangement.
Medicus Pharma completed the acquisition of Antev, a UK-based biotech company, in August 2025. Antev is developing Teverelix, a next-generation gonadotrophin-releasing hormone (GnRH) antagonist, for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.
Teverelix suppresses sex hormone production directly without an initial surge in testosterone levels. Formulated as a microcrystalline suspension, Teverelix allows for sustained release and a six-week dosing interval.
Antev completed a Phase 1 clinical trial in September 2020, demonstrating Teverelix’s tolerability and rapid testosterone suppression. In February 2023, a Phase 2a study in 50 patients with advanced prostate cancer (APC) achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met, with the probability dropping to 82.5% by Day 42.
The FDA reviewed the Phase 1 and Phase 2a data in January 2023 and provided guidance on Antev’s proposed Phase 3 trial design for Teverelix.
In December 2023, the FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.
In November 2024, the FDA approved the Phase 2b study design in AURr covering 390 patients.
In October 2025, Medicus Pharma announced a collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome.
In November 2025, Medicus Pharma received regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to treat BCC of the skin.
In December 2025, Medicus Pharma completed enrolment of 90 patients in the United States for Phase 2 clinical study (SKNJCT-003). Topline results are expected in the first quarter of 2026, with an end-of-Phase 2 meeting with the FDA anticipated in the first half of 2026.
In December 2025, Medicus Pharma announced a non-binding letter of intent with Reliant AI Inc. to collaborate on the development of an AI-driven clinical data analytics platform.
In February 2026, Medicus Pharma announced that it has received “study may proceed” clearance from the FDA to initiate its Phase 2b dose-optimization study of Teverelix® in men with advanced prostate cancer (APC).
Source: Medicus Pharma Ltd.
